AF
ARQT icon

Allworth Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Allworth Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Buy
829
+102
+14% +$2.6K ﹤0.01% 3019
2025
Q4 		$21.1K Buy
727
+141
+24% +$3.61K ﹤0.01% 2782
2025
Q3 		$11K Buy
586
+563
+2,448% +$8.88K ﹤0.01% 3081
2025
Q2 		$323 Buy
+23
New +$322 ﹤0.01% 4232
2023
Q4 		– Sell
-59
Closed -$314 – 3467
2023
Q3 		$314 Buy
59
+18
+44% +$153 ﹤0.01% 3157
2023
Q2 		$391 Buy
+41
New +$455 ﹤0.01% 2941

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allworth Financial's ARQT Position: Q1 2026 in Review

Allworth Financial increased its Arcutis Biotherapeutics (ARQT) stake by 14% in Q1 2026, buying an estimated $2.6K and bringing the position to 829 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3019.

Allworth Financial first reported a position in ARQT in Q2 2023 and has held it in 6 quarters since. The position peaked at $21.1K in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Allworth Financial held 829 shares of Arcutis Biotherapeutics worth $19.5K as of Q1 2026.
  • Allworth Financial bought 102 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.6K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3019 holding.
  • Allworth Financial first reported a position in Arcutis Biotherapeutics in Q2 2023 and has held it in 6 quarters since.
  • Allworth Financial's Arcutis Biotherapeutics position peaked at $21.1K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.